Drug
major Dr Reddy's Laboratories (DRL) has received US
health regulator's approval to market ZembraceSymTouch
(sumatriptan succinate) injection, a drug device combination product
intended for the treatment of acute migraine,
in the American market.
The
company has received an approval from the US
Food and Drug Administration (USFDA) for ZembraceSymTouch injection.
Key Facts about ZembraceSymTouch:
ü The
product is available as a pre-filled, ready-to-use, single-dose disposable
auto-injector containing 3 mg of sumatriptan.
ü Sumatriptan
is a selective 5-HT1B/ID receptor agonist.
ü The
injection is intended to be given subcutaneously.
ü ZembraceSymTouch
is specifically designed for patients who experience certain migraine episodes
and for whom a pill may not be the right option.
Key Facts about Migraine:
Ø Migraine
is a neurological disease
characterized by recurrent moderate to severe headaches often in association
with a number of autonomic nervous system symptoms.
Ø Typically,
the headache affects one half of the head,
is pulsating in nature, and lasts
from two to 72 hours.
Ø Migraines
are believed to be due to a mixture of environmental and genetic factors, about
two to three times more women than men.
Post A Comment: